B-cell depletion with the anti-CD20 antibody rituximab is highly effective for pemphigus vulgaris (PV) treatment. However, most patients experience relapse, and intravenous rituximab infusions are expensive. Therefore, cost-effective anti-CD20 therapies are desirable.
A compassionate-use investigational new drug protocol was approved to administer veltuzumab, a ...
JAMA Dermatol. Published online August 13, 2014. doi:10.1001/jamadermatol.2014.1939